AAAAAA

   
Results: 1-8 |
Results: 8
Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease - The ADMIT Study: A randomized trial
Authors: Elam, MB Hunninghake, DB Davis, KB Garg, R Johnson, C Egan, D Kostis, JB Sheps, DS Brinton, EA
Citation: Mb. Elam et al., Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease - The ADMIT Study: A randomized trial, J AM MED A, 284(10), 2000, pp. 1263-1270
Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease
Authors: Garg, R Elam, MB Crouse, JR Davis, KB Kennedy, JW Egan, D Herd, JA Hunninghake, DB Johnson, WC Kostis, JB Sheps, DS Applegate, WB
Citation: R. Garg et al., Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease, AM HEART J, 140(5), 2000, pp. 792-803
Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT)
Authors: Chesney, CM Elam, MB Herd, JA Davis, KB Garg, R Hunninghake, D Kennedy, JW Applegate, WB
Citation: Cm. Chesney et al., Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT), AM HEART J, 140(4), 2000, pp. 631-636
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
Authors: Rubins, HB Robins, SJ Collins, D Fye, CL Anderson, JW Elam, MB Faas, FH Linares, E Schaefer, EJ Schectman, G Wilt, TJ Wittes, J
Citation: Hb. Rubins et al., Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol, N ENG J MED, 341(6), 1999, pp. 410-418
Apolipoprotein B mRNA editing and apolipoprotein gene expression in the liver of hyperinsulinemic fatty Zucker rats: Relationship to very low densitylipoprotein composition
Authors: Elam, MB von Wronski, MA Cagen, L Thorngate, F Kumar, P Heimberg, M Wilcox, HG
Citation: Mb. Elam et al., Apolipoprotein B mRNA editing and apolipoprotein gene expression in the liver of hyperinsulinemic fatty Zucker rats: Relationship to very low densitylipoprotein composition, LIPIDS, 34(8), 1999, pp. 809-816
Emerging noninvasive biochemical measures to predict cardiovascular risk
Authors: Pahor, M Elam, MB Garrison, RJ Kritchevsky, SB Applegate, WB
Citation: M. Pahor et al., Emerging noninvasive biochemical measures to predict cardiovascular risk, ARCH IN MED, 159(3), 1999, pp. 237-245
Rationale and design of the arterial disease multiple intervention trial (ADMIT) pilot study
Authors: Egan, DA Garg, R Wilt, TJ Pettinger, MB Davis, KB Crouse, J Herd, JA Hunninghake, DB Sheps, DS Kostis, JB Probstfield, J Waclawiw, MA Applegate, W Elam, MB
Citation: Da. Egan et al., Rationale and design of the arterial disease multiple intervention trial (ADMIT) pilot study, AM J CARD, 83(4), 1999, pp. 569-575
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
Authors: Elam, MB Heckman, J Crouse, JR Hunninghake, DB Herd, JA Davidson, M Gordon, IL Bortey, EB Forbes, WP
Citation: Mb. Elam et al., Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication, ART THROM V, 18(12), 1998, pp. 1942-1947
Risultati: 1-8 |